Trametinib – Uses, Dosage, Side Effects, Interaction

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 74 min read
Trametinib - Uses, Dosage, Side Effects, Interaction
Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

On this page14 sections

Article Summary

Trametinib is a dual-kinase inhibitor that is used in the treatment of advanced malignant melanoma, usually in combination with dabrafenib. Trametinib therapy is associated with transient elevations in serum aminotransferase and alkaline phosphatase levels during therapy but has yet to be linked cases of clinically apparent acute liver injury. Trametinib is an orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPK/ERK kinase; MEK) 1 and...

Key Takeaways

  • This article explains Mechanism of Action in simple medical language.
  • This article explains Indications in simple medical language.
  • This article explains Contraindications in simple medical language.
  • This article explains Dosage in simple medical language.
Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.
Educational health guideWritten for patient understanding and clinical awareness.
Reviewed content workflowUse writer and reviewer profiles for stronger trust.
Emergency safety firstUrgent warning signs are highlighted below.
Choose your reading view

Patient View highlights a simple learning journey. Clinical View reveals structure, evidence, and editorial completeness.

Definition

Trametinib is a dual-kinase inhibitor that is used in the treatment of advanced , usually in combination with dabrafenib. Trametinib therapy is associated with transient elevations in serum aminotransferase and alkaline phosphatase levels during therapy but has yet to be linked cases of clinically apparent injury.

Trametinib is an orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPK/ERK kinase; MEK) 1 and 2, with potential antineoplastic activity. Upon oral administration, trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor-mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity serine/threonine and tyrosine kinases often upregulated in various cancer cell types, play a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth.

Trametinib is a pyridopyrimidine that is used (as its dimethyl sulfoxide addition compound) for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, and who have not received prior BRAF inhibitor treatment. It has a role as an EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor, an antineoplastic agent, an anticoronaviral agent, and a geroprotector. It is a pyridopyrimidine, an organofluorine compound, an organoiodine compound, a member of acetamides, a ring assembly, a member of cyclopropanes and an aromatic amine

Trametinib Dimethyl Sulfoxide is a dimethyl sulfoxide (DMSO) solvated form of trametinib, an orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPK/ERK kinase; MEK) 1 and 2, with potential antineoplastic activity. Upon oral administration, trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor-mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity serine/threonine and tyrosine kinases often upregulated in various cancer cell types, play a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth.

Trametinib dimethyl sulfoxide is an addition compound obtained by combining equimolar amounts of trametinib and dimethyl sulfoxide. Used for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, and who have not received prior BRAF inhibitor treatment. It has a role as an antineoplastic agent and an EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor. It contains dimethyl sulfoxide and trametinib.

Trametinib is an orally bioavailable mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 inhibitor. It was first approved by the FDA in May 2013 for the treatment of melanoma.[rx] It was later approved by Health Canada on July 18, 2013 [rx] and by the European Commission on June 30, 2014.[rx] Trametinib is currently approved to treat a variety of cancers with BRAF mutations, such as non-small cell lung cancer and cancer, as monotherapy or in combination with dabrafenib, a BRAF inhibitor, for improved efficacy. Originally developed by Japan Tobacco, trametinib was initially investigated for treating , but further studies for this were not pursued.[rx]

Mechanism of Action

New Window

Trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal-regulated kinase 1 _(MEK1)_ and _MEK2_ activation and of_ MEK1_ and _MEK2_ kinase activity. MEK proteins are upstream regulators of the extracellular signal-related kinase (ERK) pathway, which promotes cellular proliferation. Trametinib helps with melanoma with the BRAF V600E or V600K as the mutation results in the constitutive activation of the BRAF pathway which includes MEK1 and MEK2.

Trametinib is an anticancer agent which causes apoptosis (or programmed cell death) and inhibits cell proliferation, which are both important in the treatment of malignancies. Trametinib inhibits cell growth of various BRAF V600 mutation-positive tumors in vitro and in vivo. Trametinib is often used in combination with dabrafenib, a BRAF inhibitor. In BRAF-mutant colorectal cancer, induction of EGFR-mediated MAPK pathway re-activation has been identified as a mechanism of intrinsic resistance to BRAF inhibitors.7

Indications

New Window
  • Trametinib is indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FD-approved test. It is used in combination with [dabrafenib] for the: – Treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations. – Adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of (s), following complete resection. – Treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. – Treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options.
  • Melanoma: Trametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Trametinib monotherapy has not demonstrated activity in patients who have progressed on a prior BRAF inhibitor therapy.
  • Adjuvant treatment of melanoma: Trametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.
  • Non-small cell lung cancer (NSCLC): Trametinib in combination with dabrafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.
New Window
  • Trametinib is a dual-kinase inhibitor that is used in the treatment of advanced malignant melanoma, usually in combination with dabrafenib. Trametinib therapy is associated with transient elevations in serum aminotransferase and alkaline phosphatase levels during therapy but has yet to be linked to cases of clinically apparent acute liver injury.
  • Trametinib dimethyl sulfoxide is approved to be used alone or with dabrafenib mesylate to treat patients whose cancer has a certain mutation in the BRAF gene, including:

    • Anaplastic thyroid cancer that has spread and cannot be treated with local therapy. It is used with dabrafenib mesylate.

    • Glioma that is low grade in children aged 1 year and older who require therapy. It is used with dabrafenib mesylate.

    • Melanoma. It is used:

    • With dabrafenib mesylate in patients who have had surgery to remove cancer that has spread to the .

    • Alone or with dabrafenib mesylate in patients whose cancer cannot be removed by surgery or has spread to other parts of the body.

    • Non-small cell lung cancer that has spread to other parts of the body. It is used with dabrafenib mesylate.

    • Solid tumors. It is used with dabrafenib mesylate in adults and children aged 6 years and older whose tumors cannot be removed by surgery or have spread to other parts of the body and have gotten worse after other treatments and cannot be treated with other therapies.

  • Advanced Non-Small Cell Lung Cancer (NSCLC)
  • Locally Advanced Anaplastic Thyroid Cancer
  • Melanoma
  • Metastatic Anaplastic Thyroid Cancer
  • Metastatic Melanoma
  • Metastatic Non-Small Cell Lung Cancer
  • Stage III Melanoma
  • Unresectable Melanoma
  • Unresectable or Metastatic Solid Tumors
  • This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, a confirmatory trial(s) must show that trametinib dimethyl sulfoxide provides a clinical benefit in these patients. Trametinib dimethyl sulfoxide is also being studied in the treatment of other types of cancer.

Use in Cancer

Trametinib dimethyl sulfoxide is approved to be used alone or with dabrafenib mesylate to treat patients whose cancer has a certain mutation in the BRAF gene, including:

  • Anaplastic thyroid cancer has spread and cannot be treated with local therapy. It is used with dabrafenib mesylate.
  • Glioma is low-grade in children aged 1 year and older who require systemic therapy. It is used with dabrafenib mesylate.
  • Melanoma. It is used:
    • With dabrafenib mesylate in patients who have had surgery to remove cancer that has spread to the lymph nodes.
    • Alone or with dabrafenib mesylate in patients whose cancer cannot be removed by surgery or has spread to other parts of the body.
  • Non-small cell lung cancer has spread to other parts of the body. It is used with dabrafenib mesylate.
  • Solid tumors. It is used with dabrafenib mesylate in adults and children aged 6 years and older whose tumors cannot be removed by surgery or have spread to other parts of the body and have gotten worse after other treatments and cannot be treated with other therapies.¹

This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, a confirmatory trial(s) must show that trametinib dimethyl sulfoxide provides a clinical benefit in these patients.

Trametinib dimethyl sulfoxide is also being studied in the treatment of other types of cancer.

Contraindications

  • an increased risk of bleeding
  • detachment of the of the eye
  • a clot in the lung
  • , a disease of the
  • blood clot in a deep of the extremities
  • a body temperature higher than 101 degrees Fahrenheit
  • pregnancy
  • a patient who is producing milk and breastfeeding
  • a rupture in the wall of the stomach or intestine
  • lung tissue problem

Strengths: 0.5 mg; 2 mg

 Melanoma – Metastatic

Unresectable or Metastatic Melanoma:

  • Single agent: 2 mg orally once a day
  • Combination therapy: 2 mg orally once a day with dabrafenib (refer to the dabrafenib prescribing information for recommended dabrafenib dosing information)
  • Duration of therapy: Until or unacceptable toxicity occurs.

Adjuvant Treatment of Melanoma:

  • Combination therapy: 2 mg orally once a day with dabrafenib (refer to the dabrafenib prescribing information for recommended dabrafenib dosing information)
  • Duration of therapy: Until disease or unacceptable toxicity occurs for up to one year.
  • Confirm the presence of BRAF V600E or V600K mutation in specimens prior to initiation.
  • As a single agent for the treatment of BRAF-inhibitor treatment-naive patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test
  • In combination with dabrafenib for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test
  • In combination with dabrafenib for patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection

Non-Small Cell Lung Cancer

  • 2 mg orally once a day with dabrafenib (refer to the dabrafenib prescribing information for recommended dabrafenib dosing information)
    Duration of therapy: Until disease progression or unacceptable toxicity occurs.
  • Confirm the presence of BRAF V600E mutation in tumor specimens prior to initiation of therapy with this drug and dabrafenib.
  • In combination with dabrafenib for patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test

Thyroid Cancer

  • 2 mg orally once a day with dabrafenib (refer to the dabrafenib prescribing information for recommended dabrafenib dosing information)
    Duration of therapy: Until disease progression or unacceptable toxicity occurs.
  • Confirm the presence of BRAF V600E mutation in tumor specimens prior to initiation of therapy with this drug and dabrafenib.
  • In combination with dabrafenib for patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options

Dose Adjustments

Recommended Dose Reductions for Adverse Reactions:

  • First dose reduction: 1.5 mg orally once a day
  • Second dose reduction: 1 mg orally once a day
  • Subsequent modification: Permanently discontinue therapy if unable to tolerate 1 mg orally once a day

Venous Thromboembolism:

  • Uncomplicated or : Withhold therapy for up to 3 weeks; if improved to Grade 0 or 1, resume at a lower dose level; if not improved, permanently discontinue therapy.
  • Life threatening PE: Permanently discontinue therapy.

Cardiac Toxicity:

  • , absolute decrease in left ventricular ejection fraction (LVEF) of 10% or greater from that is below institutional lower limits of normal (LLN) from pretreatment value: Withhold therapy for up to 4 weeks; if improved to normal LVEF value, resume therapy at a lower dose; if not improved to normal LVEF value, permanently discontinue therapy.
  • Symptomatic or an absolute decrease in LVEF of greater than 20% from baseline that is below LLN: Permanently discontinue therapy.

Ocular Toxicity:

  • Retinal pigment epithelial detachments (RPED): Withhold therapy for up to 3 weeks; if improved, resume therapy at same or lower dose level; if not improved, discontinue therapy or resume at a lower dose.
  • Retinal vein occlusion: Permanently discontinue therapy.

Pulmonary Toxicity:
Interstitial lung disease/pneumonitis: Permanently discontinue therapy.

Febrile Drug Reactions:

  • Fever higher than 104F or fever complicated by rigors, hypotension, dehydration or renal failure: Withhold therapy until fever resolves, then resume at same or lower dose level.

Dermatologic Toxicity:

  • Grade 3 or 4 or intolerable Grade 2: Withhold therapy for up to 3 weeks; if improved, resume therapy at a lower dose level; if not improved, permanently discontinue therapy.

Other Adverse Reactions (dose modifications are not recommended for this drug when administered with dabrafenib for the following adverse reactions of dabrafenib: non-cutaneous malignancies and uveitis; dose modification of this drug is not required for new primary cutaneous malignancies):

  • Any Grade 3 or intolerable Grade 2 adverse reaction: Withhold therapy; if improved to Grade 0 to 1, resume therapy at a lower dose level, if not improved, permanently discontinue therapy.
  • First occurrence of any Grade 4 adverse reaction: Withhold therapy until adverse reaction improves to Grade 0 to 1, then resume therapy at a lower dose level; if not improved, permanently discontinue therapy.
  • Recurrent Grade 4 adverse reaction: Permanently discontinue therapy.

Side Effects

The Most Common

  • dry skin
  • sores on the mouth and tongue
  • dry mouth
  • vomiting
  • loss of appetite
  • change in ability to taste food
  • tiredness
  • unusual bleeding or bruising
  • bloody or black, tarry stools
  • coughing up or vomiting blood or material that looks like coffee grounds
  • nosebleed
  • severe diarrhea
  • stomach pain
  • nausea
  • fever
  • chills
  • rapid, irregular, or pounding heartbeat
  • difficulty breathing
  • chest pain
  • swelling of the face, arms, legs, ankles, or feet
  • dizziness, lightheadedness, or weakness
  • shortness of breath
  • leg pain, swelling, tenderness, redness, or warmth
  • severe headache
  • cough
  • blurred vision
  • change in vision, including seeing halos (blurred outline around objects) or colored dots
  • loss of vision
  • eye pain
  • dry, red, or swollen eyes
  • rash, red skin, or pimples
  • wart
  • a reddish bump that bleeds or does not heal
  • change in size or color of a mole
  • itching
  • blisters, ulcers, or sores on the skin or nails
  • tingling, burning, redness, swelling, peeling or flaking, blisters, or sores on the palms of the hands or soles of the feet
  • frequent urination
  • increased thirst

More common

  • Acne, pimples
  • burning, itching, and pain in hairy areas, pus at the root of the hair
  • canker sores
  • change in taste
  • dark urine
  • dry eyes
  • dry mouth
  • dry skin
  • itching, pain, redness, swelling, tenderness, or warmth on the skin
  • loosening of the fingernails
  • loss of taste
  • redness or soreness around the fingernails
  • sores, ulcers, or white spots on the lips or tongue or inside the mouth
  • swelling or inflammation of the mouth
  • thirst
  • Bleeding from the rectum or bloody stools
  • bleeding gums
  • blemishes on the skin
  • blistering, crusting, irritation, itching, or reddening of the skin
  • bloating or swelling of the face, arms, hands, lower legs, or feet
  • bloody nose
  • blurred vision
  • chest discomfort, pain, or tightness
  • cracked, dry, or scaly skin
  • coughing up blood
  • decreased urine output
  • diarrhea
  • difficulty in moving
  • difficulty with breathing or swallowing
  • dilated neck veins
  • extreme tiredness or weakness
  • fast, slow, irregular, or pounding heartbeat
  • headache
  • increased menstrual flow or vaginal bleeding
  • irregular breathing
  • joint pain
  • lightheadedness, dizziness, or fainting
  • muscle aches, cramps, pain, or stiffness
  • nervousness
  • nosebleeds
  • paralysis
  • pimples
  • pounding in the ears
  • prolonged bleeding from cuts
  • rapid weight gain
  • rash
  • red or black, tarry stools
  • red or dark brown urine
  • redness, swelling, or pain of the skin
  • scaling of the skin on the hands and feet
  • swelling of the hands, ankles, feet, or lower legs
  • tingling of the hands and feet
  • ulceration of the skin
  • unusual tiredness or weakness
  • unusual weight gain or loss

Rare

  • Change in vision
  • seeing flashes or sparks of light
  • seeing floating spots before the eyes, or a veil or curtain across part of your vision
  • stomach cramps, pain, or tenderness
  • watery or bloody diarrhea
  • Blistering, peeling, loosening of the skin
  • chills
  • itching
  • red skin lesions, often with a purple center
  • sore throat
  • sores, ulcers, or white spots in the mouth or on lips
  • swollen glands
  • unusual bleeding or bruising

Drug interactions

Pregnancy and Lactation

AU TGA pregnancy category: D
US FDA pregnancy category: Not assigned.

Pregnancy

Based on its mechanism of action and findings from animal reproduction studies, MEKINIST can cause fetal harm when administered to a pregnant woman. There is insufficient data on pregnant women exposed to MEKINIST to assess the risks. Trametinib was embryotoxic and abortifacient in rabbits at doses greater than or equal to those resulting in exposures approximately 0.3 times the human exposure at the recommended clinical dose. Advise pregnant women of the potential risk to the fetus.

Lactation

No information is available on the clinical use of trametinib during breastfeeding. Because trametinib is 97% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is 3.9 to 4.8 days and it might accumulate in the infant. The manufacturer recommends that breastfeeding be discontinued during trametinib therapy and for 4 months after the last dose.

Why is this medication prescribed?

Trametinib is used alone or in combination with dabrafenib (Tafinlar) to treat a certain type of melanoma (a type of skin cancer) that cannot be treated with surgery or that has spread to other parts of the body. It is used in combination with dabrafenib to treat and prevent the return of a certain type of melanoma after surgery to remove it and any affected lymph nodes. Trametinib is also used in combination with dabrafenib to treat a certain type of non-small-cell lung cancer (NSCLC) that has spread to nearby tissues or to other parts of the body. It is used in combination with dabrafenib to treat a certain type of thyroid cancer that has spread to nearby tissues or to other parts of the body, which cannot be treated with other therapies. Trametinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells.

How should this medicine be used?

Trametinib comes as a tablet to take by mouth. It is usually taken once a day on an empty stomach, at least 1 hour before or 2 hours after a meal. Take trametinib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take trametinib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. Do not stop taking trametinib without talking to your doctor.

Your doctor may adjust your dose of trametinib depending on your response to treatment and any side effects that you experience. Talk to your doctor about how you are feeling during your treatment.

Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient.

Other uses for this medicine

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

What special precautions should I follow?

Before taking trametinib,

  • tell your doctor and pharmacist if you are allergic to trametinib, any other medications, or any of the ingredients in trametinib tablets. Ask your pharmacist for a list of the ingredients.
  • tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take.
  • tell your doctor if you have or have ever had lung disease or breathing problems; diabetes; bleeding problems or blood clots; colitis (inflammation of the colon); stomach problems; high blood pressure; heart, eye, liver, or kidney disease; or any other medical conditions.
  • tell your doctor if you are pregnant or plan to become pregnant. You should not become pregnant while you are taking trametinib. You should use birth control to prevent pregnancy during your treatment with trametinib and for 4 months after your final dose. Talk to your doctor about birth control methods that will work for you. If you become pregnant while taking trametinib, call your doctor. Trametinib may harm the fetus.
  • tell your doctor if you are breastfeeding or plan to breastfeed. You should not breastfeed while taking trametinib and for 4 months after your final dose.
  • you should know that this medication may decrease fertility in women. Talk to your doctor about the risks of taking trametinib.

What should I know about storage and disposal of this medication?

Keep this medication in the container it came in, tightly closed, away from moisture and light, and out of the reach of children. Do not place the tablets in other containers, such as daily or weekly pill boxes. Store it in a refrigerator, but do not freeze it. Do not remove the desiccant (small packet included with medication to absorb moisture) from your bottle.

It is important to keep all medication out of sight and reach of children as many containers (such as weekly pill minders and those for eye drops, creams, patches, and inhalers) are not child-resistant and young children can open them easily. To protect young children from poisoning, always lock safety caps and immediately place the medication in a safe location – one that is up and away and out of their sight and reach. http://www.upandaway.org

Unneeded medications should be disposed of in special ways to ensure that pets, children, and other people cannot consume them. However, you should not flush this medication down the toilet. Instead, the best way to dispose of your medication is through a medicine take-back program. Talk to your pharmacist or contact your local garbage/recycling department to learn about take-back programs in your community. See the FDA’s Safe Disposal of Medicines website (http://goo.gl/c4Rm4p) for more information if you do not have access to a take-back program.

In case of emergency/overdose

In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can’t be awakened, immediately call emergency services at 911.

Symptoms of overdose may include the following:

  • vision problems

What other information should I know?

Keep all appointments with your doctor and the laboratory. Your doctor will order certain lab tests before and during your treatment to see if it is safe for you to receive trametinib and to check your body’s response to trametinib. Your doctor will also check your skin for any changes before you begin treatment, every 2 months during your treatment, and for up to 6 months after treatment. Your doctor will also check your blood pressure from time to time as needed.

Do not let anyone else take your medication. Ask your pharmacist any questions you have about refilling your prescription.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

  1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204114s007lbl.pdf
  2. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/204114s024lbl.pdf
  3. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204114s025lbl.pdf
  4. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204114s001lbl.pdf
  5. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204114s000lbl.pdf
  6. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202806s022lbl.pdf
  7. https://pubchem.ncbi.nlm.nih.gov/compound/Trametinib-dimethyl-sulfoxide
  8. https://pubchem.ncbi.nlm.nih.gov/compound/Trametinib
  9. https://en.wikipedia.org/wiki/Trametinib
  10. https://medlineplus.gov/druginfo/meds/a613040.html
  11. https://go.drugbank.com/drugs/DB08911
  12. https://www.mayoclinic.org/drugs-supplements/trametinib-oral-route/side-effects/drg-20061171
  13. https://www.drugs.com/mtm/trametinib.html
  14. ChemIDplus
    https://www.nlm.nih.gov/copyright.html
    https://pubchem.ncbi.nlm.nih.gov/substance/?source=chemidplus&sourceid=0871700173
    https://pubchem.ncbi.nlm.nih.gov/source/ChemIDplus
  15. DrugBank
    https://www.drugbank.ca/legal/terms_of_use
    https://www.drugbank.ca/drugs/DB08911
  16. EPA DSSTox
    https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources
    https://comptox.epa.gov/dashboard/DTXSID901007381
    https://comptox.epa.gov/dashboard/chemical-lists/
  17. European Chemicals Agency (ECHA)
    https://echa.europa.eu/web/guest/legal-notice
    https://echa.europa.eu/information-on-chemicals
    https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/162903
  18. FDA Global Substance Registration System (GSRS)
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    https://gsrs.ncats.nih.gov/ginas/app/beta/substances/33E86K87QN
  19. ChEBI
    http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:75998
    http://www.ebi.ac.uk/chebi/userManualForward.do#ChEBI%20Ontology
  20. FDA Pharm Classes
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm
    https://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm
  21. LiverTox
    https://www.nlm.nih.gov/copyright.html
    https://www.ncbi.nlm.nih.gov/books/n/livertox/Trametinib/
  22. NCI Thesaurus (NCIt)
    https://www.cancer.gov/policies/copyright-reuse
    https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C77908
    https://ncit.nci.nih.gov
  23. ChEMBL
    http://www.ebi.ac.uk/Information/termsofuse.html
    https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2103875/
    https://www.ebi.ac.uk/chembl/g/#browse/targets
  24. Chemical Probes Portal
    https://www.chemicalprobes.org/trametinib
  25. Comparative Toxicogenomics Database (CTD)
    http://ctdbase.org/about/legal.jsp
    https://ctdbase.org/detail.go?type=chem&acc=C560077
  26. Drug Gene Interaction database (DGIdb)
    http://www.dgidb.org/downloads
    https://www.dgidb.org/drugs/TRAMETINIB
  27. IUPHAR/BPS Guide to PHARMACOLOGY
    https://www.guidetopharmacology.org/about.jsp#license
    https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6495
    https://www.guidetopharmacology.org/targets.jsp
  28. Therapeutic Target Database (TTD)
    https://idrblab.net/ttd/data/drug/details/D04XVN
    https://idrblab.net/ttd/data/drug/details/D0S5WP
    https://idrblab.net/ttd/data/drug/details/D06AGH
  29. ClinicalTrials.gov
    https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use
    https://clinicaltrials.gov/
  30. Nature Chemical Biology
    https://pubchem.ncbi.nlm.nih.gov/substance/350080691
  31. European Medicines Agency (EMA)
    https://www.ema.europa.eu/en/about-us/legal-notice
    https://www.ema.europa.eu/en/medicines/human/EPAR/mekinist
  32. Drugs and Lactation Database (LactMed)
    https://www.nlm.nih.gov/copyright.html
    https://www.ncbi.nlm.nih.gov/books/NBK500868/
  33. EU Clinical Trials Register
    https://www.clinicaltrialsregister.eu/
  34. FDA Orange Book
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
  35. WHO Anatomical Therapeutic Chemical (ATC) Classification
    https://www.whocc.no/copyright_disclaimer/
    https://www.whocc.no/atc_ddd_index/?code=L01EE01
    https://www.whocc.no/atc_ddd_index/
  36. National Drug Code (NDC) Directory
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory
  37. Japan Chemical Substance Dictionary (Nikkaji)
    http://jglobal.jst.go.jp/en/redirect?Nikkaji_No=J3.135.455B
  38. Metabolomics Workbench
    https://www.metabolomicsworkbench.org/data/StructureData.php?RegNo=151997
  39. NCI Cancer Drugs
    https://www.cancer.gov/policies/copyright-reuse
    https://www.cancer.gov/about-cancer/treatment/drugs/trametinib
  40. NIPH Clinical Trials Search of Japan
    https://rctportal.niph.go.jp/en/
  41. NLM RxNorm Terminology
    https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html
    https://rxnav.nlm.nih.gov/id/rxnorm/1425099
  42. Pharos
    https://pharos.nih.gov/about
    https://pharos.nih.gov/ligands/T5HZJQ4ZPZ9W
  43. RCSB Protein Data Bank (RCSB PDB)
    https://www.rcsb.org/pages/policies
    https://www.rcsb.org/
  44. Springer Nature
    https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=37061692-559179997
  45. Thieme Chemistry
    https://creativecommons.org/licenses/by-nc-nd/4.0/
    https://pubchem.ncbi.nlm.nih.gov/substance/?source=22163&sourceid=37061702-188600455
  46. Wikidata
    https://creativecommons.org/publicdomain/zero/1.0/
    https://www.wikidata.org/wiki/Q7833138
  47. Wikipedia
    https://en.wikipedia.org/wiki/Trametinib
  48. https://pubchem.ncbi.nlm.nih.gov
    https://gitlab.lcsb.uni.lu/eci/pubchem-docs/-/raw/main/pfas-tree/PFAS_Tree.pdf?inline=false
  49. Medical Subject Headings (MeSH)
    https://www.nlm.nih.gov/copyright.html
    https://www.ncbi.nlm.nih.gov/mesh/67560077
    http://www.nlm.nih.gov/mesh/meshhome.html
    https://www.ncbi.nlm.nih.gov/mesh/68000970
    https://www.ncbi.nlm.nih.gov/mesh/68047428
  50. KEGG
    https://www.kegg.jp/kegg/legal.html
    http://www.genome.jp/kegg-bin/get_htext?br08303.keg
    http://www.genome.jp/kegg-bin/get_htext?br08310.keg
    http://www.genome.jp/kegg-bin/get_htext?br08330.keg
  51. UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS)
    http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html
  52. NORMAN Suspect List Exchange
    https://creativecommons.org/licenses/by/4.0/
    https://www.norman-network.com/nds/SLE/
  53. PATENTSCOPE (WIPO)
    https://pubchem.ncbi.nlm.nih.gov/substance/390643768
  54. https://www.ncbi.nlm.nih.gov/projects/linkout

RX Medical Knowledge Graph

Explore this medical topic

Continue through verified related conditions, investigations, medicines, and patient guides. These links are educational and do not replace professional medical advice.

Related medical topics

COVID‑19 Vaccine - Uses, Dosage, Side Effects, Interactions83% relationship confidence Dosage of Filgrastim - Side Effects, Interaction83% relationship confidence Estrogen Drug - Uses, Dosage, Side Effects, Interaction83% relationship confidence Filgrastim - Uses, Dosage, Side Effects, Interaction83% relationship confidence Influenza Vaccines - Uses, Dosage, Side Effect, Interaction83% relationship confidence Lipegfilgrastim - Uses, Dosage, Side Effects, Interaction83% relationship confidence Meropenem - Uses, Dosage, Side Effects, Interactions83% relationship confidence What Is Antacids? -Uses, Dosage, Side Effects, Interaction83% relationship confidence
More from this topic
  1. Vasodilator Drugs

    Vasodilator drugs relax and widen blood vessels, increasing blood flow. A few examples include ACE inhibitors, ARBs, calcium channel blockers, and nitrates.   DefinitionVasodilators are medicines that dilate...

    June 9, 2025 • Drugs (A - Z)
  2. Methamphetamine Hydrochloride – Uses, Dosage, Side Effects, Interaction

    Methamphetamine Hydrochloride is the hydrochloride salt form of methamphetamine, an amphetamine and sympathomimetic amine with CNS stimulating properties. Methamphetamine hydrochloride acts by facilitating the release of catecholamines, particularly noradrenaline and dopamine, from...

    June 5, 2025 • Drugs (A - Z)
  3. Methamphetamine – Uses, Dosage, Side Effects, Interactions

    Methamphetamine is a member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent. It has a role as a neurotoxin, a psychotropic drug,...

    June 5, 2025 • Drugs (A - Z)
  4. Vitamin D3 – Uses, Dosage, Side Effects, Interactions

    DefinitionCholecalciferol is a steroid? hormone produced in the skin when exposed to ultraviolet light or obtained from dietary sources. The active form of cholecalciferol, 1,25-dihydroxycholecalciferol (calcitriol) plays an important role...

    March 10, 2025 • Drugs (A - Z)
  5. Imidazole – Uses, Dosage, Side Effects, Interactions

    DefinitionImidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is...

    October 20, 2023 • Drugs (A - Z)
  6. Carbimazole

    Carbimazole is a member of the class of imidazoles that is methimazole in which the nitrogen-bearing hydrogen is converted into its methoxycarbonyl derivative. A prodrug for methimazole, carbimazole is...

    October 20, 2023 • Drugs (A - Z)
  7. Methylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionA thiourea antithyroid agent that inhibits the synthesis of thyroid? hormone. It is used in the treatment of hyperthyroidism?. Methylthiouracil is an organosulfur compound that is used in...

    October 20, 2023 • Drugs (A - Z)
  8. Propylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionPropylthiouracil is a Thyroid? Hormone Synthesis Inhibitor. The mechanism of action of propylthiouracil is as a Thyroid Hormone Synthesis Inhibitor. 6-propyl-2-thiouracil is a pyrimidine-thione consisting of uracil in which the...

    October 20, 2023 • Drugs (A - Z)
  9. Methimazole

    DefinitionMethimazole ( Metirox 5 and 10 mg) is a member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen that is attached to...

    October 20, 2023 • Drugs (A - Z)
  10. Mirogabalin – Uses, Dosage, Side Effects, Interactions

    DefinitionMirogabalin has been used in trials studying the treatment of Post-herpetic Neuralgia?, Pain? Associated With Fibromyalgia?, and Diabetic peripheral neuropathic pain. Mirogabalin is a medication designed...

    August 12, 2023 • Drugs (A - Z)
RX Clinical Pathway Engine

Continue through a complete learning pathway

Move from understanding the topic to symptoms, tests, treatment, medicines, monitoring, and prevention.

Search the complete library
  1. Understand the condition Begin with the essential facts and a clear explanation of the topic.
  2. Recognize symptoms Learn common symptoms, signs, and patterns of presentation.
  3. Know when to seek help Review urgent warning signs and when professional assessment may be needed.
  4. Understand causes and risks Explore causes, risk factors, mechanisms, and contributing conditions.
  5. Explore tests and diagnosis Learn how clinicians assess the condition and which investigations may be discussed.
  6. Learn treatment approaches Review general treatment categories and management principles.
  7. Understand medicines safely Continue to medicine education, uses, precautions, and monitoring.
  8. Plan monitoring and follow-up Understand monitoring, complications, rehabilitation, and follow-up learning.
  9. Review prevention and self-care Explore prevention, healthy routines, and questions to discuss with a clinician.

Conditions & Diseases

Background, symptoms, causes, diagnosis, and care.

Explore this library

Tests & Investigations

Laboratory, imaging, screening, and diagnostic education.

Explore this library

Medicines

Uses, safety, monitoring, and related medicine knowledge.

Explore this library

Cancer Knowledge

Cancer types, screening, oncology, and treatment education.

Explore this library
Doctor visit helper

Prepare before seeing a doctor

A simple rural-patient checklist to help you explain symptoms clearly, ask better questions, and avoid unsafe self-treatment.

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

  • Write when the problem started and how it changed.
  • Bring old prescriptions, investigation reports, and current medicines.
  • Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
  • Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

  • What is the most likely cause of my symptoms?
  • Which danger signs mean I should go to hospital quickly?
  • Which tests are necessary now, and which can wait?
  • How should I take medicines safely and what side effects should I watch for?
  • When should I come for follow-up?

Tests to discuss

  • Vital signs: temperature, pulse, blood pressure, oxygen saturation
  • Basic physical examination by a clinician
  • CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

  • Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
  • Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
  • Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

  • Avoid heavy lifting, sudden bending, and prolonged bed rest.
  • Use comfortable posture and gentle movement as tolerated.
  • Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

  • For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
  • Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

  • Do not start antibiotics without a proper medical decision.
  • Do not use steroid tablets or injections casually for quick relief.
  • Do not delay emergency care because of home remedies.

Get urgent help if

  • Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.
Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Medicine doctor / pediatrician for children / qualified clinician
Tests to discuss with doctor
  • Temperature chart and hydration assessment
  • CBC with platelet count if fever persists or dengue/other infection is possible
  • Urine test, malaria/dengue tests, chest evaluation, or blood culture only when clinically indicated
Questions to ask
  • What is the most likely cause of my symptoms?
  • Which warning signs mean I should go to emergency care?
  • Which tests are really needed now?
  • Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
  • Do I need antibiotics, or is this more likely viral?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Safe pathway to proper treatment

Care roadmap for: Trametinib – Uses, Dosage, Side Effects, Interaction

Use this simple roadmap to understand the next safe steps. It is educational and does not replace examination by a doctor.

Go to emergency care if you notice:
  • Severe or rapidly worsening symptoms
  • Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration
Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.
  1. Step 1

    Check danger signs first

    If danger signs are present, seek emergency care and do not wait for online information.

  2. Step 2

    Record the symptom story

    Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.

  3. Step 3

    Visit a qualified clinician

    A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.

  4. Step 4

    Do only useful tests

    Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.

  5. Step 5

    Follow up and return early if worse

    If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips
  • Take a written symptom diary and all previous prescriptions/test reports.
  • Do not hide medicines already taken, even herbal or over-the-counter medicines.
  • Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.

Internal learning pathway

Explore related RX articles

Related guides from RX Harun are grouped to help readers move from overview to symptoms, tests, treatment, and safe next steps.

Drugs (A - Z)
  1. Vasodilator Drugs Vasodilator drugs relax and widen blood vessels, increasing blood flow. A few examples include ACE inhibitors, ARBs, calcium…
  2. Methamphetamine Hydrochloride – Uses, Dosage, Side Effects, Interaction Methamphetamine Hydrochloride is the hydrochloride salt form of methamphetamine, an amphetamine and sympathomimetic amine with CNS stimulating properties. Methamphetamine…
  3. Methamphetamine – Uses, Dosage, Side Effects, Interactions Methamphetamine is a member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent.…
  4. Vitamin D3 – Uses, Dosage, Side Effects, Interactions DefinitionCholecalciferol is a steroid? hormone produced in the skin when exposed to ultraviolet light or obtained from…
  5. Imidazole – Uses, Dosage, Side Effects, Interactions DefinitionImidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of…
  6. Carbimazole Carbimazole is a member of the class of imidazoles that is methimazole in which the nitrogen-bearing hydrogen is…